CASI Pharmaceuticals (CASI) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Is CASI or BMEA more profitable?

Biomea Fusion has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -148.55%. Biomea Fusion's return on equity of -243.95% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-148.55%	-972.55%	-99.07%
Biomea Fusion	N/A	-243.95%	-140.74%

Do analysts rate CASI or BMEA?

CASI Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 75.44%. Biomea Fusion has a consensus price target of $14.80, indicating a potential upside of 666.84%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts clearly believe Biomea Fusion is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Biomea Fusion	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.17

Do insiders & institutionals have more ownership in CASI or BMEA?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 18.4% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has stronger earnings and valuation, CASI or BMEA?

CASI Pharmaceuticals has higher revenue and earnings than Biomea Fusion. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$28.54M	0.98	-$39.26M	-$2.89	-0.79
Biomea Fusion	N/A	N/A	-$138.43M	-$3.03	-0.64

Does the media prefer CASI or BMEA?

In the previous week, CASI Pharmaceuticals and CASI Pharmaceuticals both had 2 articles in the media. Biomea Fusion's average media sentiment score of 1.40 beat CASI Pharmaceuticals' score of 0.65 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, CASI or BMEA?

CASI Pharmaceuticals has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500.

Summary

Biomea Fusion beats CASI Pharmaceuticals on 9 of the 15 factors compared between the two stocks.